Sampatrilat is primarily used in the field of cardiovascular research due to its role as a dual inhibitor of both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). This dual action makes it effective in managing hypertension and heart failure by reducing blood pressure and improving cardiac function. It works by preventing the breakdown of natriuretic peptides, which promote vasodilation and sodium excretion, while also inhibiting the production of angiotensin II, a potent vasoconstrictor. Its application is particularly relevant in studies exploring novel therapeutic strategies for cardiovascular diseases, offering potential benefits in reducing morbidity and mortality associated with these conditions. Note that Sampatrilat remains an investigational compound and has not been approved for widespread clinical use.